Global Extramammary Paget Disease Market – Industry Trends and Forecast to 2029

Global Extramammary Paget Disease Market, By Type (Type 1, Type 2, Type 3), Diagnosis (Needle Biopsy, Ultrasound, Colonoscopy, Cervical Smear, Mammography), Treatment (Surgery, Radiation Therapy, Aminolevulinic Acid Based Photodynamic Therapy, Laser Ablation, Chemotherapeutic Drugs, Others), Route of Administration (Oral, Topical, Parenteral, Others), End-Users (Hospitals, Specialty Clinics, Homecare, Others), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy, Others) – Industry Trends and Forecast to 2029

Market Analysis and Size                              

Extramammary Paget disease (EMPD) is a chronic eczema-like rash that affects both men's and women's vaginal regions. Under a microscope, this disorder seems to be extremely similar to mammary Paget disease, which affects the breast. The location of the rash is the main distinction between the two. EMPD can cause rashes in the vulva, perianal region, scrotum, penis, and axilla, whereas breast Paget disease causes rashes around the nipple and areolar skin. Extramammary Paget disease is linked to a cancer in about a quarter of cases.

Data Bridge Market Research analyses that the Extramammary Paget disease market was valued at USD 204.41 million in 2021 and is expected to reach USD 308.98 million by 2029, registering a CAGR of 5.30% during the forecast period of 2022 to 2029. In addition to the market insights such as market value, growth rate, market segments, geographical coverage, market players, and market scenario, the market report curated by the Data Bridge Market Research team also includes in-depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.

Report Scope and Market Segmentation

Market Definition

Extramammary Paget disease (EPMD) is an uncommon condition characterized by a chronic skin rash in the vaginal areas that looks like eczema. Needle biopsy or ultrasound screening of regional lymph nodes are needed tests, as is the search for other malignancies using procedures such as colonoscopy, cervical smear, or mammography. Surgery is usually the preferred treatment option for EPMD. Extramammary Paget disease can be treated with advanced surgical procedures such as Mohs micrographic surgery, excisional biopsy, and vulvectomy. Surgery may not be an option for some people due to their location or recurrent disease. Radiation therapy, laser ablation, aminolevulinic acid-based photodynamic therapy and chemotherapy drugs including paclitaxel, trastuzumab , docetaxel, 5-fluorouracil, and imiquimod are then considered.

Extramammary Paget Disease Market Dynamics

Drivers

• Rising prevalence of Extramammary Paget disease

The surging prevalence of Extramammary Paget disease is a major factor driving the market's growth rate during the forecast period of 2022-2029. A pluripotent keratinocyte stem cell, Toker cell, or apocrine gland duct cell could be the cell of origin in primary extramammary Paget disease. Adenocarcinoma of the rectum, bladder, urethra, prostate, endocervix, or stomach causes secondary extramammary Paget disease, which is caused by direct extension or metastasis from another site. One-third of patients with perianal extramammary Paget disease had an underlying rectal cancer.

• Increasing investment for healthcare infrastructure

Another significant factor influencing the growth rate of Extramammary Paget disease market is the rising healthcare expenditure which helps in improving its infrastructure. Also, various government organizations aims to improve the healthcare infrastructure by increasing funding and this will further influence the market dynamics.

Furthermore, rising government initiatives to spread awareness and sedentary lifestyle of people will result in the expansion of Extramammary Paget disease market. Along with this, favourable reimbursement policies and surging adoption rate of early diagnosis will enhance the market's growth rate.

Opportunities

• Increase in the number of research and development activities       

The market's growth is fueled by an increase in the number of research and development activities. This will provide beneficial opportunities for the Extramammary Paget disease market growth.

Moreover, the market's growth is fueled by rising technological advancements in diagnostic methods and emerging new markets. These factors will provide beneficial opportunities for the Extramammary Paget disease market growth.

Restraints/Challenges

On the other hand, high cost associated with the available treatment and diagnosis will obstruct the growth rate of the market. The lack of healthcare infrastructure in developing economies and dearth of skilled professionals will challenge the Extramammary Paget disease market. Additionally, lack of awareness about rare diseases and unfavourable healthcare policies will act as restrain and further impede the growth rate of market during the forecast period of 2022-2029.

This Extramammary Paget disease market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the Extramammary Paget disease market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

Patient Epidemiology Analysis

EMPD is a rare disease, with just a few hundred instances described in the medical literature worldwide. The exact frequency is unknown. EMPD accounts for 6.5 percent of all cutaneous Paget disease cases and primarily affects patients aged 50 to 80, with a peak age of 65.3 years. Although there is a male predominance in Asia, Caucasians and women are more typically affected. The vulva is the most commonly affected location, accounting for 65 percent of EMPD cases. EMPD has also been seen in locations with altered apocrine glands, such as the external auditory canal in ceruminous carcinoma and probably the eyelid in Moll's glands carcinoma.

Extramammary Paget disease market also provides you with detailed market analysis for patient analysis, prognosis and cures. Prevalence, incidence, mortality, adherence rates are some of the data variables that are available in the report. Direct or indirect impact analyses of epidemiology to market growth are analysed to create a more robust and cohort multivariate statistical model for forecasting the market in the growth period.

Global Extramammary Paget Disease Market Scope

The Extramammary Paget disease market is segmented on the basis of type, route of administration, diagnosis, treatment, end-users and distribution channel. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Type

• Type 1
• Type 2
• Type 3

Route of Administration

• Oral
• Topical
• Parenteral
• Others

Diagnosis

• Needle Biopsy
• Ultrasound
• Colonoscopy
• Cervical Smear
• Mammography

Treatment

• Surgery
• Cryotherapy
• Mohs micrographic surgery
• Excisional biopsy
• Vulvectomy
• Radiation Therapy
• Aminolevulinic Acid Based Photodynamic Therapy
• Laser Ablation
• Chemotherapeutic Drugs
• Paclitaxel
• 5-fluorouracil
• Docetaxel
• Imiquimod
• Trastuzumab
• Others

End-Users

• Hospitals
• Specialty Clinics
• Homecare
• Others

Distribution Channel

• Hospital Pharmacy
• Retail Pharmacy
• Online Pharmacy
• Others

Extramammary Paget Disease Market Regional Analysis/Insights

The Extramammary Paget disease market is analysed and market size insights and trends are provided by country, type, route of administration, diagnosis, treatment, end-users and distribution channel as referenced above.

The countries covered in the Extramammary Paget disease market report are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America

North America dominates the Extramammary Paget disease market in terms of market share and market revenue and will continue to flourish its dominance during the forecast period. Due to the growing prevalence of Extramammary Paget disease and rising healthcare expenditure, this will further propel the market’s growth rate in this region. Additionally, growing presence of major key players will further propel the market’s growth rate in this region.

Asia-Pacific is expected to grow during the forecast period of 2022-2029 due to the development of healthcare infrastructure in this region. Also, rising government initiatives will further propel the market’s growth rate in this region.

The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points like down-stream and upstream value chain analysis, technical trends and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.   

Competitive Landscape and Extramammary Paget Disease Market Share Analysis

The Extramammary Paget disease market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to Extramammary Paget disease market.

Some of the major players operating in the Extramammary Paget disease market are:

• F. Hoffmann-La Roche Ltd. (Switzerland)
• Mylan N.V. (U.S.)
• Teva Pharmaceutical Industries Ltd. (Ireland)
• Sanofi (France)
• Pfizer Inc. (U.S.)
• GlaxoSmithKline plc (U.K.)
• Novartis AG (Switzerland)
• Merck & Co., Inc. (U.S.)
• Allergan (Ireland)
• AstraZeneca (U.K.)
• Johnson & Johnson Private Limited (U.S.)
• Hikma Pharmaceuticals PLC (U.K.)
• Bristol-Myers Squibb Company (U.S.)
• Bayer AG (Germany)
• Boehringer Ingelheim International GmbH. (Germany)
• Dr. Reddy’s Laboratories Ltd. (India)
• Gilead Sciences, Inc. (U.S.)
• Amgen Inc. (U.S.)
• Eli Lilly and Company (U.S.)
• AbbVie Inc. (U.S.)
• Lupin (India)
• Allergan (Ireland)